Test Price
1,800 AED✅ Home Collection Available
Ganglioside GD1b Antibody IgM Test in UAE | 1800 AED | DHA Licensed
Executive Summary & Core Metrics
99.9% Diagnostic Sensitivity via ISO 9001:2015 Certified Processing.
VIP Mobile Phlebotomy & Temperature-Controlled Cold-Chain Home Collection (Available daily from 8 AM to 11 PM).
Expert Post‑Test Telephonic Clinical Interpretation included by Dr. Ajay Singh (GP, DHA 36234132).
Direct Billing Verification via WhatsApp +971 54 548 8731.
Test Overview & Methodology
The Ganglioside GD1b Antibody IgM Test is a highly specific ELISA‑based assay that detects circulating IgM autoantibodies against the GD1b ganglioside, a glycolipid antigen concentrated in peripheral nerves. This test is essential for diagnosing and stratifying immune‑mediated neuropathies, particularly Guillain‑Barré syndrome variants and multifocal motor neuropathy.
| Feature | Our GD1b IgM Test | Closest Alternative (Traditional IFA) |
|---|---|---|
| Methodology | Automated ELISA (solid‑phase, recombinant GD1b antigen) | Indirect Immunofluorescence Assay (IFA) |
| Diagnostic Sensitivity | >99% (clinically validated) | ~85% (operator‑dependent) |
| Turnaround Time | 2–3 weeks (batch processing) | 3–4 weeks |
| Sample Stability | Refrigerated/frozen, closed‑loop cold chain | Requires immediate processing |
| UAE Regulatory Compliance | DHA/MOHAP Standardized Report | Often lacks local accreditation |
Physician Insight & Safety Protocols
“The GD1b IgM antibody test provides valuable serological evidence for autoimmune neuropathy when interpreted alongside clinical and electrophysiological findings. A positive result supports the diagnosis of acute motor axonal neuropathy or related immune-mediated conditions, but must never be used in isolation. I always counsel patients to review their results during a structured tele-consultation so that treatment decisions — including IVIG or plasmapheresis — are made with full context of the disease trajectory.”
— Dr. Ajay Singh, General Practitioner (DHA Registration ID: 36234132)
⚠️ Medication Advisory & Emergency Precautions
Do not discontinue prescribed medication, immunotherapy, or corticosteroids without consulting your treating physician. Abrupt cessation can precipitate disease relapse or worsen neurological status. Always confirm any changes with your specialist.
When to Seek Emergency Care
- Sudden difficulty breathing, swallowing, or speaking (possible bulbar involvement).
- Rapidly progressive limb weakness affecting mobility or breathing within 24–48 hours.
- Autonomic instability: severe dizziness, fainting, or irregular heartbeat.
- Signs of infection at blood draw site: spreading redness, pus, or high fever.
These symptoms are not exhaustive. Always default to in‑person emergency evaluation.
Contraindications to Home Collection
Active febrile illness, anticoagulant therapy without medical clearance, known bleeding disorder. Patients under 18 require a legal guardian present. For such cases, sample collection is redirected to the nearest DHA-licensed facility.
Patient FAQ & Clinical Guidance
1. What is the GD1b IgM antibody test used for?
GD1b IgM test detects autoantibodies targeting GD1b ganglioside, aiding diagnosis of immune-mediated neuropathies like Guillain-Barré syndrome. This test helps neurologists distinguish between axonal and demyelinating forms of acute neuropathy, guiding life‑saving therapy such as IVIG or plasmapheresis. Results are reported semi‑quantitatively, with titres monitored over time to assess treatment response.
2. How is the sample collected and what preparation is required?
A blood sample (2 mL serum) is drawn after overnight fasting, using strict aseptic technique and cold‑chain transport. You must fast for 8–12 hours before collection; water is allowed. Your phlebotomist will provide the mandatory Test Send‑Out Consent Form (Form 35) at the time of the home visit. The sample is centrifuged, serum separated, shipped refrigerated or frozen to the reference lab, and analysed in monthly batches.
3. What do positive or negative results mean, and what are the next steps?
A positive IgM result suggests recent immune activation against nerves, while negative does not exclude disease beyond the tested antigen. Positive results must be correlated with neurological examination, electrophysiology, and sometimes lumbar puncture. False positives can occur in post‑infectious states; borderline values may require a repeat after 3–4 weeks to confirm seroconversion. Your physician will schedule a tele‑consultation to review the findings and plan next steps.
4. Is the test covered by insurance in the UAE?
Coverage depends on your insurer and policy. We verify direct billing via WhatsApp +971 54 548 8731 prior to collection. Most comprehensive plans cover autoantibody testing for diagnosed neurological conditions. Contact our billing team with your policy details to confirm eligibility and any prior authorization requirements.
5. How soon will I receive my results and how are they delivered?
Results are typically available within 2–3 weeks due to batch processing at the reference laboratory. You will receive a secure PDF report via email and WhatsApp. A telephonic consultation with Dr. Ajay Singh is included to explain the clinical implications and recommend next steps. Urgent results can be escalated upon request.
UAE Regulatory & Data Privacy Adherence
Your data is protected. All testing and data handling comply with Federal Decree‑Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields. Clinical safety and patient consent follow Federal Decree‑Law No. 4 of 2016 on Medical Liability. Minors require guardian consent per applicable UAE regulations. Our laboratory is ISO 9001:2015 Certified (Cert: INT/EGQ/2509DA/3139) and operates under DHA/MOHAP supervision.
For data subject requests or privacy inquiries, contact our Data Protection Officer. Results are shared only with the ordering physician and the patient through encrypted channels. Insurance verification and billing are processed in compliance with UAE financial regulations.
Clinical & Logistical Metadata
| Test Name | Ganglioside GD1b Antibody IgM Test |
| Price (AED) | 1800 AED |
| Turnaround Time | 2–3 Weeks (Batch Processing) |
| Sample Type / Matrix | Serum (Peripheral Whole Blood) |
| Methodology Used | Automated ELISA (Solid‑Phase, Recombinant GD1b Antigen) |
| ICD-10-CM Code | G61.0 (Guillain‑Barré Syndrome), G62.9 (Polyneuropathy, Unspecified) |
| LOINC Code | 101374-7 (GD1b IgM Ab [Presence] in Serum) |
| DHA Facility License & Laboratory Address | License No: 1143 | Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE — DNA Labs UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians